{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Volpp KG"],"funding":["National Center for Advancing Translational Sciences","Penn Medicine","NCATS NIH HHS","National Institutes of Health"],"pagination":["208-222"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11560706"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["278"],"pubmed_abstract":["<h4>Rationales</h4>Atherosclerotic Cardiovascular Disease (ASCVD) is the leading cause of morbidity and mortality in the United States. Suboptimal control of hypertension and hyperlipidemia are common factors contributing to ASCVD risk. The Penn Medicine Healthy Heart (PMHH) Study is a randomized clinical trial testing the effectiveness of a system designed to offload work from primary care clinicians and improve patient follow-through with risk reduction strategies by using a centralized team of nonclinical navigators and advanced practice providers, remote monitoring, and bi-directional text messaging, augmented by behavioral science engagement strategies. The intervention builds on prior nonrandomized evaluations of these design elements that demonstrated significant improvement in pati"],"journal":["American heart journal"],"pubmed_title":["Design and rationale of penn medicine healthy heart, a randomized trial of effectiveness of a centrally organized approach to blood pressure and cholesterol improvement among patients at elevated risk of atherosclerotic cardiovascular disease."],"pmcid":["PMC11560706"],"funding_grant_id":["UL1 TR001878-06","UL1 TR001878"],"pubmed_authors":["Ashcraft LE","Putt ME","Glanz K","Fanaroff AC","Clark K","Volpp KG","Kellum W","Russell LB","Snider C","Mehta SJ","Cohen JB","Norton LA","Mahraj K","Balasta M","Wood J","Asch DA","Jacoby D","Zhu J","Press MJ","Bakshi S","Rareside C"],"additional_accession":[]},"is_claimable":false,"name":"Design and rationale of penn medicine healthy heart, a randomized trial of effectiveness of a centrally organized approach to blood pressure and cholesterol improvement among patients at elevated risk of atherosclerotic cardiovascular disease.","description":"<h4>Rationales</h4>Atherosclerotic Cardiovascular Disease (ASCVD) is the leading cause of morbidity and mortality in the United States. Suboptimal control of hypertension and hyperlipidemia are common factors contributing to ASCVD risk. The Penn Medicine Healthy Heart (PMHH) Study is a randomized clinical trial testing the effectiveness of a system designed to offload work from primary care clinicians and improve patient follow-through with risk reduction strategies by using a centralized team of nonclinical navigators and advanced practice providers, remote monitoring, and bi-directional text messaging, augmented by behavioral science engagement strategies. The intervention builds on prior nonrandomized evaluations of these design elements that demonstrated significant improvement in pati","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-06T14:04:53.877Z","creation":"2026-05-31T03:09:56.749Z"},"accession":"S-EPMC11560706","cross_references":{"pubmed":["39341482"],"doi":["10.1016/j.ahj.2024.09.029"]}}